Last reviewed · How we verify
Insulin lispro low mix
Insulin lispro low mix is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiological insulin secretion by providing both mealtime and basal insulin coverage.
Insulin lispro low mix is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiological insulin secretion by providing both mealtime and basal insulin coverage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin lispro low mix |
|---|---|
| Also known as | LM, Low Mix, Humalog |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin combination (biphasic insulin) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This biphasic insulin formulation contains approximately 25% rapid-acting insulin lispro (which begins working within 15 minutes) and 75% intermediate-acting insulin lispro protamine (which provides sustained coverage over several hours). The combination allows for a single injection that addresses both postprandial (after-meal) glucose spikes and basal insulin requirements, reducing the need for multiple daily injections while maintaining glycemic control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
- Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes (PHASE4)
- 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine (PHASE4)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
- A Study for Patients With Diabetes Mellitus (IOPA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin lispro low mix CI brief — competitive landscape report
- Insulin lispro low mix updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI